Archives
-
Fluorouracil: From TS Inhibition to Resistance Strategy
2026-09-28
A translational perspective on how Fluorouracil and 5-Fluorouracil connect thymidylate synthase inhibition with replication stress, transporter-mediated resistance, and more disciplined solid-tumor research design.
-
SGI-1027 and Everolimus Disrupt Lysosomes in RCC
2026-09-28
The study reports that SGI-1027, a DNMT1 inhibitor, induces vacuolation and methuosis in renal cancer cells and cooperates with everolimus to promote lysosomal membrane permeability, apoptosis, and GSDME-dependent pyroptosis. Its preclinical findings identify lysosomal vulnerability as a potential route to strengthen everolimus activity, while leaving clinical benefit and the mechanisms of resistance to be tested further.
-
EZ Cap™ Cre mRNA (m1Ψ): Evidence & Workflow
2026-09-27
EZ Cap™ Cre mRNA (m1Ψ) is a Cap 1, m1Ψ-modified Cre recombinase mRNA designed for transient Cre expression and loxP-site recombination. A cardiac microphysiological-system study supports the importance of delivery formulation, but does not establish that this specific product was tested or that its performance is independent of the delivery vehicle.
-
Sodium chloride B7288: Preparation and QC
2026-09-26
Sodium chloride B7288 provides a water-soluble inorganic salt for setting ionic strength and supporting osmotic balance in buffers, biochemical assays, and cell culture media. Use it for a defined NaCl contribution, not as a pH buffer or a DMSO- or ethanol-based stock; prepared solutions should be used promptly rather than stored long term.
-
Small-Molecule uPAR–uPA Inhibition Limits Metastasis
2026-09-25
The study synthesized and evaluated IPR-803, a small-molecule inhibitor of the uPAR–uPA interaction, connecting direct receptor binding with reduced breast cancer cell invasion and lower lung metastatic burden in mice. Its binding, cellular, and pharmacokinetic findings make the compound a useful research template, while the preclinical design and exposure data also highlight important limits on interpreting efficacy.
-
KG-501 Workflows for CREB–KIX Assays in Cancer Models
2026-09-25
Use KG-501 to test whether CREB–coactivator signaling contributes to transcriptional and macrophage responses—not as a stand-in for a TLR4-specific inhibitor. This workflow pairs dose and viability controls with the macrophage readouts used in colitis-associated colorectal cancer research.
-
HyperScribe™ K1066: mRNA Design for Disc Research
2026-09-24
Explore how HyperScribe™ All in One mRNA Synthesis Kit II (K1066) can support controlled mRNA experiments inspired by emerging intervertebral disc research. We connect kit components to a preclinical fibroblast strategy while distinguishing practical workflow considerations from findings the study has actually established.
-
Mildronate Lipidoids for Lower-Inflammation mRNA Vaccines
2026-09-24
The 2024 ACS Nano study reports mLNP-69, a lipid nanoparticle formulation using a low dose of mildronate-derived cationic lipid to deliver mRNA while reducing local inflammation relative to an SM102-based comparator. Its prophylactic and therapeutic B16OVA melanoma results support further preclinical evaluation, but do not establish clinical safety or broad effectiveness across mRNA formulations.
-
Reducing Pollen Interference in EEM Bioaerosol Detection
2026-09-23
Zhang and colleagues tested how pollen affects excitation–emission matrix fluorescence classification of hazardous bioaerosol-related samples and evaluated spectral transformations with a random forest classifier. Fast Fourier transform processing produced the strongest reported result, improving classification accuracy by 9.2% to 89.24%, while highlighting the need to account for natural biological backgrounds in rapid detection systems.
-
Wnt/NR2F2 Drives Platinum Resistance in Brain Metastasis
2026-09-23
The reference study identifies a Wnt/NR2F2/GPX4 axis that links high glutathione consumption to ferroptosis suppression and acquired platinum resistance in lung cancer-derived brain metastases. Its integrated metabolomic, proteomic, genetic, and biochemical analyses provide a mechanistic framework for studying therapy resistance, while also highlighting the need for caution when translating pathway findings into chemical activation workflows.
-
Fluorouracil Workflows for Solid Tumor Research
2026-09-22
Build reproducible Fluorouracil and 5-Fluorouracil assays around concentration-response data, mechanism-linked controls, and stability-aware handling. This guide connects cytotoxicity screening with resistance biology, including practical extensions for colon cancer research, breast cancer research, and renal carcinoma models.
-
HyperScribe™ mRNA Synthesis for CAR mRNA
2026-09-22
Explore how an mRNA synthesis kit can support CD19 CAR mRNA development, from cap and nucleotide design to functional assay planning. This article translates recent in vivo CAR-T findings into practical molecular quality and workflow decisions.
-
AptaBLE: Deep Learning for Aptamer Design
2026-09-21
AptaBLE combines pretrained protein and nucleic acid encoders with symmetric bidirectional cross-attention to predict aptamer–protein binding across variable-length sequences. The preprint also reports two de novo generation strategies that produced target-binding aptamers with reported dissociation constants as low as 31 nM, positioning sequence-based modeling as a complement to SELEX rather than a replacement for experimental validation.
-
FLOT1–FOSL2–EphA2 Signaling in Alzheimer’s Disease
2026-09-21
The reference study identifies a FLOT1–FOSL2–EphA2 regulatory axis that links microglial molecular control to p38/MAPK signaling, neuroinflammation, and cognitive impairment in APP/PS1 mice. Its combination of interaction, transcriptional, pathway-perturbation, histological, and behavioral assays provides a mechanistic framework for studying microglial polarization in Alzheimer’s disease.
-
JXY, TLR4, and M1 Polarization in CAC
2026-09-20
The reference study shows that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer in mice while shifting macrophages toward an M1-like phenotype through TLR4-associated signaling. Its integrated in vivo, histological, molecular, and functional design supports immune-microenvironment modulation as a mechanism of action, while also highlighting the need for more specific pathway validation.